Age Related Macular Degeneration – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Age Related Macular Degeneration – Pipeline Review, H2 2016’, provides an overview of the Age Related Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration

The report reviews pipeline therapeutics for Age Related Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Age Related Macular Degeneration therapeutics and enlists all their major and minor projects

The report assesses Age Related Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

AC Immune SA

Achillion Pharmaceuticals Inc

Aciont Inc

Acucela Inc

AdAlta Ltd

Adverum Biotechnologies Inc

Aerie Pharmaceuticals Inc

Aerpio Therapeutics Inc

Alimera Sciences Inc

Alkeus Pharmaceuticals Inc

Allergan Plc

Allinky Biopharma

Alteogen Inc

Amakem NV

Amarna Therapeutics BV

Ampio Pharmaceuticals Inc

Amyndas Pharmaceuticals LLC

ANP Technologies Inc

Apellis Pharmaceuticals Inc

Apexigen Inc

Applied Genetic Technologies Corp

Astellas Pharma Inc

Benitec Biopharma Ltd

Biokine Therapeutics Ltd

BioMAS Ltd

Biomics Biotechnologies Co Ltd

Biophytis SAS

BLR Bio LLC

Boehringer Ingelheim GmbH

Caladrius Biosciences Inc

Catalyst Biosciences Inc

Cell Cure Neurosciences Ltd

Cell Medica Ltd

Charlesson LLC

Chong Kun Dang Pharmaceutical Corp

Cipla Ltd

Clanotech AB

Clearside BioMedical Inc

Coherus BioSciences Inc

Colby Pharmaceutical Company

Crinetics Pharmaceuticals Inc

Critical Pharmaceuticals Ltd

Daiichi Sankyo Company Ltd

Diffusion Pharmaceuticals Inc

Dong-A Socio Holdings Co Ltd

Eleven Biotherapeutics Inc.

Elsalys Biotech SAS

Exonate Ltd

F. Hoffmann-La Roche Ltd

FirstString Research Inc

Foamix Pharmaceuticals Ltd

Formycon AG

Gene Techno Science Co Ltd

Genentech Inc

GenSight Biologics SA

GlaxoSmithKline Plc

Graybug Vision Inc

Grupo Ferrer Internacional SA

HanAll Biopharma Co Ltd

Huabo Biopharm Co Ltd

iCo Therapeutics Inc.

Icon Bioscience Inc

Iconic Therapeutics Inc

Inception Sciences Inc

Innovent Biologics Inc

Intellect Neurosciences Inc

International Stem Cell Corp

Ionis Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

Johnson & Johnson

Kala Pharmaceuticals Inc

Kodiak Sciences Inc

Lead Discovery Center GmbH

LeadArtis SL

M's Science Corp

Mabion SA

MacuCLEAR Inc

MeiraGTx Ltd

Mitotech SA

Mitsubishi Tanabe Pharma Corp

Mor Research Application Ltd

Navigen Pharmaceuticals Inc

Navya Biologicals Pvt Ltd

Neovacs SA

Neumedicines Inc

Neuroptis Biotech

Novartis AG

NovelMed Therapeutics Inc

Ocular Therapeutix Inc

Ohr Pharmaceutical Inc

Omeros Corp

Ophthotech Corp

Oxford BioMedica Plc

PanOptica Inc

Pfenex Inc

Pfizer Inc

Precision Ocular Ltd

Promedior Inc

pSivida Corp

QLT Inc

Ra Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

RegenxBio Inc

Retrotope Inc

Ribomic Inc

RXi Pharmaceuticals Corp

Samumed LLC

SanBio Inc

Santen Pharmaceutical Co Ltd

SciFluor Life Sciences LLC

Stealth BioTherapeutics Inc

Sucampo Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

TRACON Pharmaceuticals Inc

TWi Pharmaceuticals Inc

Tyrogenex Inc

Wellstat Ophthalmics Corp

Xbrane Biopharma AB

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Age Related Macular Degeneration Overview 8

Therapeutics Development 9

Age Related Macular Degeneration - Therapeutics under Development by Companies 11

Age Related Macular Degeneration - Therapeutics under Investigation by Universities/Institutes 21

Age Related Macular Degeneration - Pipeline Products Glance 23

Age Related Macular Degeneration - Products under Development by Companies 26

Age Related Macular Degeneration - Products under Investigation by Universities/Institutes 39

Age Related Macular Degeneration - Companies Involved in Therapeutics Development 40

Age Related Macular Degeneration - Therapeutics Assessment 160

Drug Profiles 176

Age Related Macular Degeneration - Dormant Projects 513

Age Related Macular Degeneration - Discontinued Products 528

Age Related Macular Degeneration - Product Development Milestones 530

Appendix 539

List of Tables

List of Tables

Number of Products under Development for Age Related Macular Degeneration, H2 2016 32

Number of Products under Development for Age Related Macular Degeneration – Comparative Analysis, H2 2016 33

Number of Products under Development by Companies, H2 2016 34

Number of Products under Development by Companies, H2 2016 (Contd..1) 35

Number of Products under Development by Companies, H2 2016 (Contd..2) 36

Number of Products under Development by Companies, H2 2016 (Contd..3) 37

Number of Products under Development by Companies, H2 2016 (Contd..4) 38

Number of Products under Development by Companies, H2 2016 (Contd..5) 39

Number of Products under Development by Companies, H2 2016 (Contd..6) 40

Number of Products under Development by Companies, H2 2016 (Contd..7) 41

Number of Products under Development by Companies, H2 2016 (Contd..8) 42

Number of Products under Development by Companies, H2 2016 (Contd..9) 43

Number of Products under Investigation by Universities/Institutes, H2 2016 45

Comparative Analysis by Late Stage Development, H2 2016 46

Comparative Analysis by Clinical Stage Development, H2 2016 47

Comparative Analysis by Early Stage Development, H2 2016 48

Products under Development by Companies, H2 2016 49

Products under Development by Companies, H2 2016 (Contd..1) 50

Products under Development by Companies, H2 2016 (Contd..2) 51

Products under Development by Companies, H2 2016 (Contd..3) 52

Products under Development by Companies, H2 2016 (Contd..4) 53

Products under Development by Companies, H2 2016 (Contd..5) 54

Products under Development by Companies, H2 2016 (Contd..6) 55

Products under Development by Companies, H2 2016 (Contd..7) 56

Products under Development by Companies, H2 2016 (Contd..8) 57

Products under Development by Companies, H2 2016 (Contd..9) 58

Products under Development by Companies, H2 2016 (Contd..10) 59

Products under Development by Companies, H2 2016 (Contd..11) 60

Products under Development by Companies, H2 2016 (Contd..12) 61

Products under Investigation by Universities/Institutes, H2 2016 62

Age Related Macular Degeneration – Pipeline by 3SBio Inc, H2 2016 63

Age Related Macular Degeneration – Pipeline by AC Immune SA, H2 2016 64

Age Related Macular Degeneration – Pipeline by Achillion Pharmaceuticals Inc, H2 2016 65

Age Related Macular Degeneration – Pipeline by Aciont Inc, H2 2016 66

Age Related Macular Degeneration – Pipeline by Acucela Inc, H2 2016 67

Age Related Macular Degeneration – Pipeline by AdAlta Ltd, H2 2016 68

Age Related Macular Degeneration – Pipeline by Adverum Biotechnologies Inc, H2 2016 69

Age Related Macular Degeneration – Pipeline by Aerie Pharmaceuticals Inc, H2 2016 70

Age Related Macular Degeneration – Pipeline by Aerpio Therapeutics Inc, H2 2016 71

Age Related Macular Degeneration – Pipeline by Alimera Sciences Inc, H2 2016 72

Age Related Macular Degeneration – Pipeline by Alkeus Pharmaceuticals Inc, H2 2016 73

Age Related Macular Degeneration – Pipeline by Allergan Plc, H2 2016 74

Age Related Macular Degeneration – Pipeline by Allinky Biopharma, H2 2016 75

Age Related Macular Degeneration – Pipeline by Alteogen Inc, H2 2016 76

Age Related Macular Degeneration – Pipeline by Amakem NV, H2 2016 77

Age Related Macular Degeneration – Pipeline by Amarna Therapeutics BV, H2 2016 78

Age Related Macular Degeneration – Pipeline by Ampio Pharmaceuticals Inc, H2 2016 79

Age Related Macular Degeneration – Pipeline by Amyndas Pharmaceuticals LLC, H2 2016 80

Age Related Macular Degeneration – Pipeline by ANP Technologies Inc, H2 2016 81

Age Related Macular Degeneration – Pipeline by Apellis Pharmaceuticals Inc, H2 2016 82

Age Related Macular Degeneration – Pipeline by Apexigen Inc, H2 2016 83

Age Related Macular Degeneration – Pipeline by Applied Genetic Technologies Corp, H2 2016 84

Age Related Macular Degeneration – Pipeline by Astellas Pharma Inc, H2 2016 85

Age Related Macular Degeneration – Pipeline by Benitec Biopharma Ltd, H2 2016 86

Age Related Macular Degeneration – Pipeline by Biokine Therapeutics Ltd, H2 2016 87

Age Related Macular Degeneration – Pipeline by BioMAS Ltd, H2 2016 88

Age Related Macular Degeneration – Pipeline by Biomics Biotechnologies Co Ltd, H2 2016 89

Age Related Macular Degeneration – Pipeline by Biophytis SAS, H2 2016 90

Age Related Macular Degeneration – Pipeline by BLR Bio LLC, H2 2016 91

Age Related Macular Degeneration – Pipeline by Boehringer Ingelheim GmbH, H2 2016 92

Age Related Macular Degeneration – Pipeline by Caladrius Biosciences Inc, H2 2016 93

Age Related Macular Degeneration – Pipeline by Catalyst Biosciences Inc, H2 2016 94

Age Related Macular Degeneration – Pipeline by Cell Cure Neurosciences Ltd, H2 2016 95

Age Related Macular Degeneration – Pipeline by Cell Medica Ltd, H2 2016 96

Age Related Macular Degeneration – Pipeline by Charlesson LLC, H2 2016 97

Age Related Macular Degeneration – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 98

Age Related Macular Degeneration – Pipeline by Cipla Ltd, H2 2016 99

Age Related Macular Degeneration – Pipeline by Clanotech AB, H2 2016 100

Age Related Macular Degeneration – Pipeline by Clearside BioMedical Inc, H2 2016 101

Age Related Macular Degeneration – Pipeline by Coherus BioSciences Inc, H2 2016 102

Age Related Macular Degeneration – Pipeline by Colby Pharmaceutical Company, H2 2016 103

Age Related Macular Degeneration – Pipeline by Crinetics Pharmaceuticals Inc, H2 2016 104

Age Related Macular Degeneration – Pipeline by Critical Pharmaceuticals Ltd, H2 2016 105

Age Related Macular Degeneration – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 106

Age Related Macular Degeneration – Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 107

Age Related Macular Degeneration – Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 108

Age Related Macular Degeneration – Pipeline by Eleven Biotherapeutics Inc., H2 2016 109

Age Related Macular Degeneration – Pipeline by Elsalys Biotech SAS, H2 2016 110

Age Related Macular Degeneration – Pipeline by Exonate Ltd, H2 2016 111

Age Related Macular Degeneration – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 112

Age Related Macular Degeneration – Pipeline by FirstString Research Inc, H2 2016 113

Age Related Macular Degeneration – Pipeline by Foamix Pharmaceuticals Ltd, H2 2016 114

Age Related Macular Degeneration – Pipeline by Formycon AG, H2 2016 115

Age Related Macular Degeneration – Pipeline by Gene Techno Science Co Ltd, H2 2016 116

Age Related Macular Degeneration – Pipeline by Genentech Inc, H2 2016 117

Age Related Macular Degeneration – Pipeline by GenSight Biologics SA, H2 2016 118

Age Related Macular Degeneration – Pipeline by GlaxoSmithKline Plc, H2 2016 119

Age Related Macular Degeneration – Pipeline by Graybug Vision Inc, H2 2016 120

Age Related Macular Degeneration – Pipeline by Grupo Ferrer Internacional SA, H2 2016 121

Age Related Macular Degeneration – Pipeline by HanAll Biopharma Co Ltd, H2 2016 122

Age Related Macular Degeneration – Pipeline by Huabo Biopharm Co Ltd, H2 2016 123

Age Related Macular Degeneration – Pipeline by iCo Therapeutics Inc., H2 2016 124

Age Related Macular Degeneration – Pipeline by Icon Bioscience Inc, H2 2016 125

Age Related Macular Degeneration – Pipeline by Iconic Therapeutics Inc, H2 2016 126

Age Related Macular Degeneration – Pipeline by Inception Sciences Inc, H2 2016 127

Age Related Macular Degeneration – Pipeline by Innovent Biologics Inc, H2 2016 128

Age Related Macular Degeneration – Pipeline by Intellect Neurosciences Inc, H2 2016 129

Age Related Macular Degeneration – Pipeline by International Stem Cell Corp, H2 2016 130

Age Related Macular Degeneration – Pipeline by Ionis Pharmaceuticals Inc, H2 2016 131

Age Related Macular Degeneration – Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 132

Age Related Macular Degeneration – Pipeline by Johnson & Johnson, H2 2016 133

Age Related Macular Degeneration – Pipeline by Kala Pharmaceuticals Inc, H2 2016 134

Age Related Macular Degeneration – Pipeline by Kodiak Sciences Inc, H2 2016 135

Age Related Macular Degeneration – Pipeline by Lead Discovery Center GmbH, H2 2016 136

Age Related Macular Degeneration – Pipeline by LeadArtis SL, H2 2016 137

Age Related Macular Degeneration – Pipeline by M's Science Corp, H2 2016 138

Age Related Macular Degeneration – Pipeline by Mabion SA, H2 2016 139

Age Related Macular Degeneration – Pipeline by MacuCLEAR Inc, H2 2016 140

Age Related Macular Degeneration – Pipeline by MeiraGTx Ltd, H2 2016 141

Age Related Macular Degeneration – Pipeline by Mitotech SA, H2 2016 142

Age Related Macular Degeneration – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 143

Age Related Macular Degeneration – Pipeline by Mor Research Application Ltd, H2 2016 144

Age Related Macular Degeneration – Pipeline by Navigen Pharmaceuticals Inc, H2 2016 145

Age Related Macular Degeneration – Pipeline by Navya Biologicals Pvt Ltd, H2 2016 146

Age Related Macular Degeneration – Pipeline by Neovacs SA, H2 2016 147

Age Related Macular Degeneration – Pipeline by Neumedicines Inc, H2 2016 148

Age Related Macular Degeneration – Pipeline by Neuroptis Biotech, H2 2016 149

Age Related Macular Degeneration – Pipeline by Novartis AG, H2 2016 150

Age Related Macular Degeneration – Pipeline by NovelMed Therapeutics Inc, H2 2016 151

Age Related Macular Degeneration – Pipeline by Ocular Therapeutix Inc, H2 2016 152

Age Related Macular Degeneration – Pipeline by Ohr Pharmaceutical Inc, H2 2016 153

Age Related Macular Degeneration – Pipeline by Omeros Corp, H2 2016 154

Age Related Macular Degeneration – Pipeline by Ophthotech Corp, H2 2016 155

Age Related Macular Degeneration – Pipeline by Oxford BioMedica Plc, H2 2016 156

Age Related Macular Degeneration – Pipeline by PanOptica Inc, H2 2016 157

Age Related Macular Degeneration – Pipeline by Pfenex Inc, H2 2016 158

Age Related Macular Degeneration – Pipeline by Pfizer Inc, H2 2016 159

Age Related Macular Degeneration – Pipeline by Precision Ocular Ltd, H2 2016 160

Age Related Macular Degeneration – Pipeline by Promedior Inc, H2 2016 161

Age Related Macular Degeneration – Pipeline by pSivida Corp, H2 2016 162

Age Related Macular Degeneration – Pipeline by QLT Inc, H2 2016 163

Age Related Macular Degeneration – Pipeline by Ra Pharmaceuticals Inc, H2 2016 164

Age Related Macular Degeneration – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 165

Age Related Macular Degeneration – Pipeline by RegenxBio Inc, H2 2016 166

Age Related Macular Degeneration – Pipeline by Retrotope Inc, H2 2016 167

Age Related Macular Degeneration – Pipeline by Ribomic Inc, H2 2016 168

Age Related Macular Degeneration – Pipeline by RXi Pharmaceuticals Corp, H2 2016 169

Age Related Macular Degeneration – Pipeline by Samumed LLC, H2 2016 170

Age Related Macular Degeneration – Pipeline by SanBio Inc, H2 2016 171

Age Related Macular Degeneration – Pipeline by Santen Pharmaceutical Co Ltd, H2 2016 172

Age Related Macular Degeneration – Pipeline by SciFluor Life Sciences LLC, H2 2016 173

Age Related Macular Degeneration – Pipeline by Stealth BioTherapeutics Inc, H2 2016 174

Age Related Macular Degeneration – Pipeline by Sucampo Pharmaceuticals Inc, H2 2016 175

Age Related Macular Degeneration – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 176

Age Related Macular Degeneration – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 177

Age Related Macular Degeneration – Pipeline by TRACON Pharmaceuticals Inc, H2 2016 178

Age Related Macular Degeneration – Pipeline by TWi Pharmaceuticals Inc, H2 2016 179

Age Related Macular Degeneration – Pipeline by Tyrogenex Inc, H2 2016 180

Age Related Macular Degeneration – Pipeline by Wellstat Ophthalmics Corp, H2 2016 181

Age Related Macular Degeneration – Pipeline by Xbrane Biopharma AB, H2 2016 182

Assessment by Monotherapy Products, H2 2016 183

Assessment by Combination Products, H2 2016 184

Number of Products by Stage and Target, H2 2016 186

Number of Products by Stage and Mechanism of Action, H2 2016 191

Number of Products by Stage and Route of Administration, H2 2016 196

Number of Products by Stage and Molecule Type, H2 2016 198

Age Related Macular Degeneration – Dormant Projects, H2 2016 536

Age Related Macular Degeneration – Dormant Projects (Contd..1), H2 2016 537

Age Related Macular Degeneration – Dormant Projects (Contd..2), H2 2016 538

Age Related Macular Degeneration – Dormant Projects (Contd..3), H2 2016 539

Age Related Macular Degeneration – Dormant Projects (Contd..4), H2 2016 540

Age Related Macular Degeneration – Dormant Projects (Contd..5), H2 2016 541

Age Related Macular Degeneration – Dormant Projects (Contd..6), H2 2016 542

Age Related Macular Degeneration – Dormant Projects (Contd..7), H2 2016 543

Age Related Macular Degeneration – Dormant Projects (Contd..8), H2 2016 544

Age Related Macular Degeneration – Dormant Projects (Contd..9), H2 2016 545

Age Related Macular Degeneration – Dormant Projects (Contd..10), H2 2016 546

Age Related Macular Degeneration – Dormant Projects (Contd..11), H2 2016 547

Age Related Macular Degeneration – Dormant Projects (Contd..12), H2 2016 548

Age Related Macular Degeneration – Dormant Projects (Contd..13), H2 2016 549

Age Related Macular Degeneration – Dormant Projects (Contd..14), H2 2016 550

Age Related Macular Degeneration – Discontinued Products, H2 2016 551

Age Related Macular Degeneration – Discontinued Products (Contd..1), H2 2016 552

List of Figures

List of Figures

Number of Products under Development for Age Related Macular Degeneration, H2 2016 32

Number of Products under Development for Age Related Macular Degeneration – Comparative Analysis, H2 2016 33

Number of Products under Development by Companies, H2 2016 34

Number of Products under Investigation by Universities/Institutes, H2 2016 44

Comparative Analysis by Late Stage Development, H2 2016 46

Comparative Analysis by Clinical Stage Development, H2 2016 47

Comparative Analysis by Early Stage Products, H2 2016 48

Assessment by Monotherapy Products, H2 2016 183

Number of Products by Top 10 Targets, H2 2016 185

Number of Products by Stage and Top 10 Targets, H2 2016 185

Number of Products by Top 10 Mechanism of Actions, H2 2016 190

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 190

Number of Products by Top 10 Routes of Administration, H2 2016 195

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 195

Number of Products by Top 10 Molecule Types, H2 2016 197

Number of Products by Stage and Top 10 Molecule Types, H2 2016 197

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared